DDInter1971 DDInter1180
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Zonisamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
Zonisamide {u} (Compound) binds {v} (Gene) SCN1B
Zonisamide {u} (Compound) upregulates {v} (Gene) KDM5A
Zonisamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonamides
Zonisamide {u} (Compound) downregulates {v} (Gene) PIN1
Zonisamide {u} (Compound) causes {v} (Side Effect) Somnolence
Zonisamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentoxyverine
Zonisamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Zonisamide {u} may lead to a major life threatening interaction when taken with {v} Cyclizine
Zonisamide {u} may lead to a major life threatening interaction when taken with {v} Doxylamine
Zonisamide (Compound) treats epilepsy syndrome (Disease)
Zonisamide (Compound) binds SCN1B (Gene)
Zonisamide (Compound) upregulates KDM5A (Gene)
Zonisamide (Compound) is included by Sulfonamides (Pharmacologic Class)
Zonisamide (Compound) downregulates PIN1 (Gene)
Zonisamide (Compound) causes Somnolence (Side Effect)
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Zonisamide may lead to a major life threatening interaction when taken with Cyclizine
Zonisamide may lead to a major life threatening interaction when taken with Doxylamine